KRAS and acute myeloid leukemia: In our study, TET2 mutation apparently associated with resistance to venetoclax in combination with A1331825 or bimiralisib, possibly due to presence of concurrent mutations in KRAS, PTPN11, or TP53 genes in the primary AML samples.